Experimental CAR-T therapy targets Hard-to-Treat brain cancer
NCT ID NCT07062627
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study is testing a new treatment called Anbal-cel for people with relapsed or refractory primary or secondary central nervous system lymphoma. Anbal-cel is a CAR-T cell therapy made from the patient's own immune cells. The study will enroll 12 participants to see if the treatment is safe and effective. Participants will receive a single infusion of Anbal-cel and be monitored closely for at least 7 days in the hospital.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anbal-cel (a CAR-T cell therapy made from the patient's own immune cells)
What this could lead to
If successful, this could offer a new treatment option for patients with hard-to-treat central nervous system lymphoma that has come back or not responded to other therapies.
What could go wrong
This is a very small pilot study with only 12 participants, so results may not apply to everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome and neurological problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••